|
CONTACTS
00 33 (0)5 67 69 04 15 |
|
EQUIPE 2 : PATHOGÉNIE ET COMMENSALISME DES ENTEROBACTÉRIES
TEAM 2 : PATHOGENESIS AND COMMENSALISM OF ENTEROBACTERIA |
|
Mini CV
Dr. Oswald is a trained veterinarian (DVM). He graduated (PhD) in 1990 and worked then since 1994 at the Uniformed Services University of Health Sciences in Bethesda (USA). Until 2009, he worked as an INRA research director at the veterinary school of Toulouse (France). In 2009, he was appointed as professor at the medical faculty of the university of Toulouse. He is now professor of bacteriology at the faculty of medicine of Toulouse and hospital practitioner in the laboratory of bacteriology of the university hospital (CHU). He is an expert in cellular microbiology and molecular biology of pathogenic Escherichia coli. His main research interest is in studying toxins. His research group is working on the integration of human and animal research to decipher the thin line between commensal and pathogenic enterobacteria. Several publications generated by the team represent milestones in the understanding of bacterial pathogenicity especially discovery of new toxins.
Education and career
Education and career
- 1987 D.V.M., National Veterinary School of Toulouse, Toulouse, France
- 1987-1990 Laboratory of infectious diseases and immunology, INRA, Nouzilly, France
- 1991 Ph.D. in Microbiology, University Claude Bernard, Lyon, France
- 1991-1994 USUHS, School of Medicine, Bethesda, USA
- 1994-2010 Team leader at INRA U1225 "Host-pathogen interactions", Veterinary School
- of Toulouse, France
- 1997 Habilitation to direct research (HDR), Toulouse University, France
- 2009-2014 Deputy director of the laboratory of bacteriology at the university hospital of
- Toulouse, France
- 2009-2015 Team leader, Inserm U1043 Center for Pathophysiology of Toulouse-Purpan
- 2016-present Team leader Inserm U1220 Digestive Health Research Institute, France
- 2014-present Head of the Laboratory of bacteriology at the university hospital of Toulouse.
- 2016-present Deputy director of the Digestive Health Research Institute.
research/project
RESEARCH INTERESTS:
Our goal is to use a multidisciplinary approach to understand the pathogenicity and the impact on human and animal health of different E. coli pathotypes and to decipher the fine barrier between pathogenicity and commensalism. Our projects lead us to look both at the ability of these enterobacteria to cause diseases (acute infections, cancers, chronic inflammatory diseases, …) but also to colonize the digestive tract, their natural reservoir. Our work has led us to take a more general interest in the modes of action of probiotics and in ways of reducing the intestinal carriage of pathogenic and more generally antibiotic-resistant bacteria.
Our goal is to use a multidisciplinary approach to understand the pathogenicity and the impact on human and animal health of different E. coli pathotypes and to decipher the fine barrier between pathogenicity and commensalism. Our projects lead us to look both at the ability of these enterobacteria to cause diseases (acute infections, cancers, chronic inflammatory diseases, …) but also to colonize the digestive tract, their natural reservoir. Our work has led us to take a more general interest in the modes of action of probiotics and in ways of reducing the intestinal carriage of pathogenic and more generally antibiotic-resistant bacteria.
scientific production Selected Publications in peer-reviewed journals (10):
- Chagneau CV. Massip C. Bossuet-Greif N. Fremez C. Motta J. P. Shima A. Besson C.
Le Faouder P. Cenac N. Roth M. P. Coppin H. Fontanie M. Martin P,.Nougayrede J. P.
Oswald E. Uropathogenic E. coli induces DNA damage in the bladder. PLoS Pathog. 2021 Feb 25;17(2):e1009310. - Massip C, Branchu P , Bossuet-Greif N , Chagneau CV, Gaillard D , Martin P, Boury M , Sécher T, Dubois D , Nougayrède JP, Oswald E. Deciphering the interplay between the genotoxic and probiotic activities of Escherichia coli Nissle 1917. PLoS Pathog. 2019 Sep 23;15(9):e1008029.
Pérez-Berezo T, Pujo J, Martin P, Le Faouder P, Galano JM, Guy A, Knauf C, Tabet JC, Tronnet S, Barreau F, Heuillet M, Dietrich G, Bertrand-Michel J, Durand T, Oswald E, Cenac N. Identification of an analgesic lipopeptide produced by the probiotic Escherichia coli strain Nissle 1917. Nat Commun. 2017 Nov 3;8(1):1314. - Payros D, Dobrindt U, Martin P, Secher T, Bracarense AP, Boury M, Laffitte J, Pinton P, Oswald E, Oswald IP. The Food Contaminant Deoxynivalenol Exacerbates the Genotoxicity of Gut Microbiota. mBio. 2017 Mar 14;8(2):e00007-17.
- Martin P, Marcq I, Magistro G, Penary M, Garcie C, Payros D, Boury M, Olier M, Nougayrède N, Audebert M, Chalut C, Schubert S, Oswald E. Interplay between siderophores and colibactin genotoxin biosynthetic pathways in Escherichia coli. PLoS Pathog. 2013;9(7):e1003437.
- Jubelin G, Taieb F, Duda DM, Hsu Y, Samba-Louaka A, Nobe R, Penary M, Watrin C, Nougayrède JP, Schulman BA, Stebbins CE, Oswald E.Pathogenic bacteria target NEDD8-conjugated cullins to hijack host-cell signaling pathways. PLoS Pathog. 2010 Sep 30;6(9):e1001128.
- Cuevas-Ramos G, Petit CR, Marcq I, Boury M, Oswald E, Nougayrède JP. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11537-42.
- Nougayrède JP, Homburg S, Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G, Buchrieser C, Hacker J, Dobrindt U, Oswald E. Escherichia coliinduces DNA double-strand breaks in eukaryotic cells. Science. 2006 Aug 11;313(5788):848-51.
- Oswald E, Sugai M, Labigne A, Wu HC, Fiorentini C, Boquet P, O'Brien AD. Cytotoxic necrotizing factor type 2 produced by virulent Escherichia coli modifies the small GTP-binding proteins Rho involved in assembly of actin stress fibers. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3814-8.
